1. Home
  2. DTSQ vs APLT Comparison

DTSQ vs APLT Comparison

Compare DTSQ & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DTSQ
  • APLT
  • Stock Information
  • Founded
  • DTSQ 2022
  • APLT 2016
  • Country
  • DTSQ United States
  • APLT United States
  • Employees
  • DTSQ N/A
  • APLT N/A
  • Industry
  • DTSQ
  • APLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DTSQ
  • APLT Health Care
  • Exchange
  • DTSQ NYSE
  • APLT Nasdaq
  • Market Cap
  • DTSQ 89.8M
  • APLT 80.3M
  • IPO Year
  • DTSQ 2024
  • APLT 2019
  • Fundamental
  • Price
  • DTSQ $10.15
  • APLT $0.61
  • Analyst Decision
  • DTSQ
  • APLT Buy
  • Analyst Count
  • DTSQ 0
  • APLT 7
  • Target Price
  • DTSQ N/A
  • APLT $6.10
  • AVG Volume (30 Days)
  • DTSQ 19.8K
  • APLT 5.8M
  • Earning Date
  • DTSQ 01-01-0001
  • APLT 03-05-2025
  • Dividend Yield
  • DTSQ N/A
  • APLT N/A
  • EPS Growth
  • DTSQ N/A
  • APLT N/A
  • EPS
  • DTSQ 0.17
  • APLT N/A
  • Revenue
  • DTSQ N/A
  • APLT N/A
  • Revenue This Year
  • DTSQ N/A
  • APLT N/A
  • Revenue Next Year
  • DTSQ N/A
  • APLT $2,622.90
  • P/E Ratio
  • DTSQ $61.02
  • APLT N/A
  • Revenue Growth
  • DTSQ N/A
  • APLT N/A
  • 52 Week Low
  • DTSQ $9.96
  • APLT $0.54
  • 52 Week High
  • DTSQ $10.15
  • APLT $10.62
  • Technical
  • Relative Strength Index (RSI)
  • DTSQ N/A
  • APLT 27.09
  • Support Level
  • DTSQ N/A
  • APLT $0.54
  • Resistance Level
  • DTSQ N/A
  • APLT $0.64
  • Average True Range (ATR)
  • DTSQ 0.00
  • APLT 0.07
  • MACD
  • DTSQ 0.00
  • APLT 0.12
  • Stochastic Oscillator
  • DTSQ 0.00
  • APLT 31.65

About DTSQ DT CLOUD STAR ACQUISITION CORP

DT Cloud Star Acquisition Corp is a blank check company.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: